All In Biotech

Free tool

FAERS Monitor: Pliaglis

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021717 or its brand name (Pliaglis, Lidocaine, Tetracaine). Reports on generic versions are filed under their own applications.

Reports

45

Serious

23

51% of reports

Hospitalization

5

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • erythema22
  • swelling face9
  • pruritus8
  • skin burning sensation5
  • angioedema3
  • blister3
  • dizziness3
  • drug ineffective3
  • eyelid oedema3
  • skin swelling3
  • somnolence3
  • application site erythema2
  • deformity2
  • feeling hot2
  • headache2

Reports by year received

View as table
YearReports
20134
201416
20159
20165
20172
20181
20193
20211
20231
20253

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,114 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
skin swellingSignal3161.654.2332
eyelid oedemaSignal3120.740.4246
deformity2100.025.8110
swelling faceSignal964.636.0503
erythemaSignal2250.037.11,018
application site erythema235.79.237
skin burning sensationSignal532.614.3124
angioedemaSignal331.710.661
blisterSignal325.08.447
feeling hot215.23.914
pruritusSignal89.75.255
somnolenceSignal37.02.310
dizziness32.80.92
headache21.50.40
drug ineffective31.10.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.